Rare diseases
Investigational molecules
Locations
Back to Austria95 clinical trials in St. Poelten, Austria across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease
AustriaStudy on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke
AustriaStudy of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema
AustriaStudy on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis
AustriaStudy of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema
AustriaStudy Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma
AustriaStudy Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
AustriaStudy Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma
AustriaStudy of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma
AustriaStudy on the Safety and Effectiveness of Vibrio Alginolyticus Collagenase for Patients with Dupuytren's Contracture
AustriaStudy on Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma
AustriaThe busiest research cities in the country
What the registry says about research in the country
The cardiovascular diseases research activity in St. Pölten focuses on improving outcomes for people with high-risk heart and vascular conditions. Trials are examining whether new approaches can better reduce major cardiovascular events and ease the burden of complex heart disease.
These studies aim to test treatment effectiveness and lower the risk of serious complications in patients with difficult-to-manage cardiovascular conditions.
Research in eye diseases is centered on neovascular age-related macular degeneration, with an emphasis on making care more practical in everyday clinical settings. The work reflects a strong interest in improving how patients are monitored and treated.
In St. Pölten, this area of research is helping evaluate ways to support better eye care while reducing treatment burden for patients and clinics.
Immune system diseases are represented by trials in allergic rhinoconjunctivitis and chronic hepatitis D infection. These studies are exploring new options to manage immune-related conditions and improve symptom control.
The research is designed to assess whether emerging therapies can offer better relief or disease control for patients living with persistent immune-driven illnesses.
Neoplasm research in St. Pölten spans both solid tumors and advanced cancer care, including studies in melanoma, hepatocellular carcinoma, and metastatic pancreatic ductal adenocarcinoma. The goal is to improve treatment effectiveness and survival in cancers that can be hard to treat.
These trials are testing new cancer treatment strategies and comparing them with established care to find better options for patients.
Work in virus diseases is addressing chronic hepatitis D, a serious viral infection that can lead to long-term liver damage. The studies are focused on finding more effective ways to control the disease.
This area of research is aimed at evaluating new therapies against current treatment options and improving care for patients with persistent viral illness.
Clinical trials in psychiatry and psychology are centered on mild to moderate major depressive disorder. The research is looking at whether new treatment options can better reduce depressive symptoms and support recovery.
These studies are intended to clarify treatment benefit and help identify therapies that may offer meaningful relief for people living with depression.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
